Mechanisms regulating skin pigmentation: The rise and fall of complexion coloration

International Journal of Molecular Sciences

Volumn 10, Issue 9, 2009, Pages 4066-4087

  Ebanks, Jody P ^a,b   Wickett, R Randall ^a   Boissy, Raymond E ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Depigmenting agents; Hyperpigmentation; Melanin; Pigment; Tyrosinase

Indexed keywords

2 HYDROXYACID; 5 [(3 AMINOPROPYL)PHOSPHINOOXY] 2 (HYDROXYMETHYL) 4H PYRAN 4 ONE; ALOESIN; ANTIOXIDANT; ARBUTIN; AZELAIC ACID; BMY 28565; CORTICOSTEROID; COSMETIC; DEOXYARBUTIN; DEPIGMENTING AGENT; FLAVONOID; GENTISIC ACID; HYDROQUINONE; HYDROXYSTILBENE; KOJIC ACID; LINOLEIC ACID; LIQUIRITIN; MELANIN; MEQUINOL; MONOPHENOL MONOOXYGENASE; N ACETYL 4 CYSTEAMINYLPHENOL; PHENOL DERIVATIVE; PIGMENT; PLANT EXTRACT; RESVERATROL; RETINOIC ACID; RETINOID; SALICYLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; CHEMICAL STRUCTURE; CHLOASMA; CONTACT DERMATITIS; CREAM; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRY SKIN; ELECTRON MICROSCOPY; ENZYME INHIBITION; ENZYME REGULATION; ERYTHEMA; GLYCYRRHIZA GLABRA; HUMAN; HYPERPIGMENTATION; KERATINOCYTE; LENTIGO; MELANOCYTE; MELANOGENESIS; MELANOMA CELL; MELANOSIS; MELANOSOME; NONHUMAN; OCHRONOSIS; PHOTOAGING; REVIEW; SKIN ATROPHY; SKIN INFLAMMATION; SKIN IRRITATION; SKIN PIGMENTATION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

DEPIGMENTING AGENTS; HYPERPIGMENTATION; MELANIN; PIGMENT; TYROSINASE;

ANIMALS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MELANOCYTES; MELANOSOMES; MONOPHENOL MONOOXYGENASE; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SKIN PIGMENTATION;

EID: 70350050360     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms10094066     Document Type: Review

References (118)

1. Turner, W.; Taylor, J.; Tchen, T. Melanosome formation in the goldfish: The role of multivesicular bodies. J. Ultra. Res. 1975, 51, 16-31.
2. Boissy, R.; Huizing, M.; Gahl, W. Biogenesis of melanosomes. In The Pigmentary System: Physiology and Pathophysiology, 2nd ed.; Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.P., Eds.; Blackwell Publishing Ltd.: Oxford, UK, 2006; pp. 155-170.
3. Boissy, R. Melanosome transfer to and translocation in the keratinocyte. Exp. Dermatol. 2003, 12, 5-12.
4. Urabe, K.; Nakayama, J.; Hori, Y. Mixed epidermal and dermal hypermelanoses. In The Pigmentary System: Physiology and Pathophysiology; Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.P., Eds.; Oxford University Press: New York, NY, USA, 1998; pp. 909-913.
5. Virador, V.; Matsunaga, N.; Matsunaga, J.; Valencia, J.; Oldham, R.; Kameyama, K.; Peck, G.; Ferrans, V.; Vieira, W.; Abdel-Malek, Z.; Hearing, V. Production of melanocyte-specific antibodies to human melanosomal proteins: Expression patterns in normal human skin and in cutaneous pigmented lesions. Pigment Cell Res. 2001, 14, 289-297. (Pubitemid 32812123)
6. Parvez, S.; Kang, M.; Chung, H.-S.; Cho, C.; Hong, M.-C.; Shin, M.-K.; Bae, H. Survey and mechanism of skin depigmentation and lightening agents. Phytother. Res. 2006, 20, 921-934.
7. Ando, H.; Kondoh, H.; Ichihashi, M.; Hearing, V. Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase. J. Invest. Dermatol. 2007, 127, 751-761. (Pubitemid 46437203)
8. Sturm, R.; Teasdale, R.; Box, N. Human pigmentation genes: Identification, structure and consequences of polymorphic variation. Gene 2001, 277, 49-62. (Pubitemid 32972108)
9. García-Borrón, J.; Solano, F. Molecular anatomy of tyrosinase and its related proteins: Beyond the histidine-bound metal catalytic center. Pigment Cell Res. 2002, 15, 162-173. (Pubitemid 34608974)
10. Briganti, S.; Camera, E.; Picardo, M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res. 2003, 16, 101-110.
11. Yamaguchi, Y.; Brenner, M.; Hearing, V. The regulation of skin pigmentation. J. Biol. Chem. 2007, 282, 27557-27561.
12. Ito, S. A chemist's view of melanogenesis. Pigment Cell Res. 2003, 16, 230-236.
13. Shibahara, S.; Takeda, K.; Yasumoto, K.; Udono, T.; Watanabe, K.; Saito, H.; Takahashi, K. Microphthalmia-associated transcription factor (MITF): Multiplicity in structure, function, and regulation. J. Investig. Dermatol. Symp. Proc. 2001, 6, 99-104. (Pubitemid 33758613)
14. Tachibana, M.; Takeda, K.; Nobukuni, Y.; Urabe, K.; Long, J.; Meyers, K.; Aaronson, S.; Miki, T. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. Nat. Genet. 1996, 14, 50-54. (Pubitemid 26301546)
15. Levy, C.; Khaled, M.; Fisher, D. MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 2006, 12, 406-414.
16. Takeda, K.; Shibahara, S. Transcriptional regulation of melanocyte function. In The Pigmentary System: Physiology and Pathophysiology, 2nd ed.; Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.P., Eds.; Blackwell Publishing Ltd.: Oxford, UK, 2006; pp. 242-260.
17. Steingrímsson, E.; Copeland, N.; Jenkins, N. Melanocytes and the microphthalmia transcription factor network. Annu. Rev. Genet. 2004, 38, 365-411.
18. Lin, C.; Babiarz, L.; Liebel, F.; Roydon Price, E.; Kizoulis, M.; Gendimenico, G.; Fisher, D.; Seiberg, M. Modulation of microphthalmia-associated transcription factor gene expression alters skin pigmentation. J. Invest. Dermatol. 2002, 119, 1330-1340. (Pubitemid 36005617)
19. Yasumoto, K.; Yokoyama, K.; Shibata, K.; Tomita, Y.; Shibahara, S. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol. Cell. Biol. 1994, 14, 8058-8070. (Pubitemid 24373554)
20. Solano, F.; Briganti, S.; Picardo, M.; Ghanem, G. Hypopigmenting agents: An updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006, 90, 550-571. (Pubitemid 44674109)
21. Saha, B.; Sing, S.; Sarkar, C.; Bera, R.; Ratha, J.; Tobin, D.; Bhadra, R. Activation of the Mitf promoter by lipid-stimulated activation of p38-stress signalling to CREB. Pigment Cell Res. 2006, 19, 595-605. (Pubitemid 44674111)
22. Kim, D.; Park, S.; Park, K. Transforming growth factor-β1 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation. Int. J. Biochem. Cell Biol. 2004, 36, 1482-1491. (Pubitemid 38625828)
23. Yang, G.; Li, Y.; Nishimura, E.; Xin, H.; Zhou, A.; Guo, Y.; Dong, L.; Denning, M.; Nickoloff, B.; Cui, R. Inhibition of PAX3 by TGF-β modulates melanocyte viability. Mol. Cell 2008, 32, 554-563.
24. Englaro, W.; Bertolotto, C.; Busca, R.; Brunet, A.; Pages, G.; Ortonne, J.; Ballotti, R. Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J. Biol. Chem. 1998, 273, 9966-9970. (Pubitemid 28183097)
25. Kim, D.; Park, S.; Kwon, S.; Park, E.; Huh, C.; Youn, S.W.; Park, K. Sphingosylphosphorylcholine-induced ERK activation inhibits melanin synthesis in human melanocytes. Pigment Cell Res. 2006, 19, 146-153. (Pubitemid 43363277)
26. Kim, D.; Hwang, E.; Lee, J.; Kim, S.; Kwon, S.; Park, K. Sphingosine-1-phosphate decreases melanin synthesis via sustained ERK activation and subsequent MITF degradation. J. Cell Sci. 2003, 116, 1699-1706. (Pubitemid 36582157)
27. Kim, D.; Kim, S.; Chung, J.; Kim, K.; Eun, H.; Park, K. Delayed ERK activation by ceramide reduces melanin synthesis in human melanocytes. Cell. Signal. 2002, 14, 779-785. (Pubitemid 34597185)
28. Hemesath, T.; Price, E.; Takemoto, C.; Badalian, T.; Fisher, D. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998, 391, 298-301. (Pubitemid 28099019)
29. Wu, M.; Hemesath, T.; Takemoto, C.; Horstmann, M.; Wells, A.; Price, E.; Fisher, D.Z.; Fisher, D.E. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 2000, 14, 301-312.
30. Xu, W.; Gong, L.; Haddad, M.; Bischof, O.; Campisi, J.; Yeh, E.; Medrano, E. Regulation of microphthalmia-associated transcription factor MITF protein levels by association with the ubiquitin-conjugating enzyme hUBC9. Exp. Cell Res. 2000, 255, 135-143. (Pubitemid 30143848)
31. Kim, D.; Park, S.; Kwon, S.; Youn, S.; Park, K. Effects of lysophosphatidic acid on melanogenesis. Chem. Phys. Lipids 2004, 127, 199-206.
32. Widlund, H.; Fisher, D. Microphthalamia-associated transcription factor: A critical regulator of pigment cell development and survival. Oncogene 2003, 22, 3035-3041. (Pubitemid 36713753)
33. McGill, G.; Horstmann, M.; Widlund, H.; Du, J.; Motyckova, G.; Nishimura, E.; Lin, Y.L.; Ramaswamy, S.; Avery, W.; Ding, H.; Jordan, S.; Jackson, I.; Korsmeyer, S.; Golub, T.; Fisher, D. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002, 109, 707-718. (Pubitemid 34722267)
34. Buscà, R.; Berra, E.; Gaggioli, C.; Khaled, M.; Bille, K.; Marchetti, B.; Thyss, R.; Fitsialos, G.; Larribère, L.; Bertolotto, C.; Virolle, T.; Barbry, P.; Pouysségur, J.; Ponzio, G.; Ballotti, R. Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J. Cell Biol. 2005, 170, 49-59. (Pubitemid 40994095)
35. Hornyak, T.; Jiang, S.; Guzman, E.; Scissors, B.; Tuchinda, C.; He, H.; Neville, J.; Strickland, F. Mitf dosage as a primary determinant of melanocyte survival after ultraviolet irradiation. Pigment Cell Melanoma Res. 2009, 22, 307-318.
36. Negriou, G.; Branza-Nichita, N.; Petrescu, A.; Dwek, R.; Petrescu, S. Protein specific N-glycosylation of tyrosinase and tyrosinase related protein-1 in B16 mouse melanoma cells. Biochem. J. 1999, 344, 659-665. (Pubitemid 30032513)
37. Branza-Nichita, N.; Petrescu, A.; Negroiu, G.; Dwek, R.; Petrescu, S. N-Glycosylation processing and glycoprotein folding-Lessons from the tyrosinase-related proteins. Chem. Rev. 2000, 100, 4697-4711. (Pubitemid 32090364)
38. Imokawa, G.; Mishima, Y. Functional analysis of tyrosinase isozymes of cultured malignant melanoma cells during the recovery period following interrupted melanogenesis induced by glycosylation inhibitors. J. Invest. Dermatol. 1984, 83, 196-201. (Pubitemid 14063908)
39. Mishima, Y.; Imokawa, G. Selective aberration and pigment loss in melanosomes of malignant melanoma cells in vitro by glycosylation inhibitors: Premelanosomes as glycoproteins. J. Invest. Dermatol. 1984, 81, 106-114.
40. Terao, M.; Tomita, K.; Oki, T.; Tabe, L.; Gianni, M.; Garattini, E. Inhibition of melanogenesis by BMY-28565, a novel compound depressing tyrosinase activity in B16 melanoma cells. Biochem. Pharmacol. 1992, 43, 183-189.
41. Land, E.; Ramsden, C.; Riley, P. Toxicological aspects of melanin and melanogenesis. In The Pigmentary System: Physiology and Pathophysiology, 2nd ed.; Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.P., Eds.; Blackwell Publishing Ltd.: Oxford, UK, 2006; pp. 354-394.
42. Choi, H.; Ahn, S.; Chang, H.; Cho, N.; Joo, K.; Lee, B.; Chang, I.; Hwang, J. Influence of N-glycan processing disruption on tyrosinase and melanin synthesis in HM3KO melanoma cells. Exp. Dermatol. 2006, 16, 110-117. (Pubitemid 46040488)
43. Franchi, J.; Coutadeur, M.; Marteau, C.; Mersel, M.; Kupferberg, A. Depigmenting effects of calcium D-pantetheine-S-sulfonate on human melanocytes. Pigment Cell Res. 2000, 35, 165-171. (Pubitemid 30400282)
44. Maresca, V.; Flori, E.; Cardinali, G.; Briganti, S.; Lombardi, D.; Mileo, A.; Paggi, M.; Picardo, M. Ferritin light chain down-modulation generates depigmentation in human metastatic melanoma cells by influencing tyrosinase maturation. J. Cell. Physiol. 2006, 206, 843-848. (Pubitemid 43191060)
45. Imokawa, G. Analysis of initial melanogenesis including tyrosinase transfer and melanosome differentiation through interrupted melanization by glutathione. J. Invest. Dermatol. 1989, 93, 100-107. (Pubitemid 19183321)
46. Villarama, C.; Maibach, H. Glutathione as a depigmenting agent: An overview. Int. J. Cosmet. Sci. 2005, 27, 147-153.
47. Nordlund, J.; Grimes, P.; Ortonne, J. The safety of hydroquinone. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 781-787.
48. Halder, R.; Nordlund, J. Topical treatment of pigmentary disorders. In The Pigmentary System: Physiology and Pathophysiology, 2nd ed.; Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.P., Eds.; Blackwell Publishing Ltd.: Oxford, UK, 2006; pp. 1165-1174.
49. Draelos, Z. Skin lightening preparations and the hydroquinone controversy. Dermatol. Ther. 2007, 20, 308-313. (Pubitemid 350197161)
50. Picardo, M.; Carrera, M. New and experimental treatments of cloasma and other hypermelanoses. Dermatol. Clin. 2007, 25, 353-362. (Pubitemid 47088898)
51. Badreshia-Bansal, S.; Draelos, Z. Insight into skin lightening cosmeceuticals for women of color. J. Drugs Dermatol. 2007, 6, 32-39.
52. Ni-Komatsu, L.; Tong, C.; Chen, G.; Brindzei, N.; Orlow, S. Identification of quinolines that inhibit melanogenesis by altering tyrosinase family trafficking. Mol. Pharmacol. 2008, 74, 1576-1586.
53. Chakraborty, A.; Funasaka, Y.; Komoto, M.; Ichihashi, M. Effect of arbutin on melanogenic proteins in human melanocytes. Pigment Cell Res. 1998, 11, 206-212. (Pubitemid 128531454)
54. Chawla, S.; deLong, M.; Visscher, M.; Wickett, R.; Manga, P.; Boissy, R. Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives. Br. J. Dermatol. 2008, 159, 1267-1274.
55. Boissy, R.; Visscher, M.; DeLong, M. DeoxyArbutin: A novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp. Dermatol. 2005, 14, 601-608.
56. Hamed, S.; Sriwiriyanont, P.; deLong, M.; Visscher, M.; Wickett, R.; Boissy, R. Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent. J. Cos. Sci. 2006, 57, 291-308.
57. Petit, L.; Piérard, G. Skin-lightening products revisited. Int. J. Cosmet. Sci. 2003, 25, 169-181.
58. Colby, S.; Schwartzel, E.; Huber, F.; Highton, A.; Altman, D.; Epinette, W.; Lyon, E. A promising new treatment for solar lentigines. J. Drugs Dermatol. 2003, 2, 147-152.
59. Keeling, J.; Cardona, L.; Benitez, A.; Epstein, R.; Rendon, M. Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: A case series and review of the literature. Cutis 2008, 81, 179-183.
60. Jimbow, K. N-Acetyl-4-S-Cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch. Dermatol. 1991, 127, 1528-1534.
61. Ferguson, J.; Rogers, P.M.; Kelland, L.R.; Robins, D.J. Synthesis and antimelanoma activity of sterically congested tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol. Oncol. Res. 2005, 15, 87-94.
62. Kim, D.; Hwang, J.; Baek, H.; Kim, K.; Lee, B.; Chang, I.; Kang, H.; Lee, O. Development of 5- [(3-aminopropyl)phosphinooxy]-2-(hydroxymethyl)-4H-pyran- 4-one as a novel whitening agent. Chem. Pharm. Bull. 2003, 51, 113-116. (Pubitemid 41701979)
63. Kim, Y.; Uyama, H. Tyrosinase inhibitors from natural and synthetic sources: Structure, inhibition mechanism and perspective for the future. Cell. Mol. Life Sci. 2005, 62, 1707-1723. (Pubitemid 41176052)
64. Parvez, S.; Kang, M.; Chung, H.; Bae, H. Naturally occuring tyrosinase inhibitors: Mechanism and application in skin health, cosmetics and agriculture industries. Phytother. Res. 2007, 21, 805-816. (Pubitemid 47407639)
65. Grimes, P. Melasma: Etiologic and therapeutic considerations. Arch. Dermatol. 1995, 131, 1453-1457.
66. Baliña, L.; Graupe, K. The treatment of melasma 20% azeiaic acid versus 4% hydroquinone cream. Int. J. Dermatol. 1991, 30, 893-895.
67. Fitton, A.; Goa, K. Azelaic acid: A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991, 41, 780-798.
68. Kubo, I.; Kinst-Hori, I.; Kubo, Y.; Yamagiwa, Y.; Kamikawa, T.; Haraguchi, H. Molecular design of antibrowing agents. J. Agric. Food Chem. 2000, 48, 1393-1399.
69. Jones, K.; Hughes, J.; Hong, M.; Jia, Q.; Orndorff, S. Modulation of melanogenesis by aloesin: A competitive inhibitor of tyrosinase. Pigment Cell Res. 2002, 15, 335-340.
70. Zhu, W.; Gao, J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J. Investig. Dermatol. Symp. Proc. 2008, 13, 20-24.
71. Jin, Y.; Lee, S.; Chung, M.; Park, J.; Park, Y.I.; Cho, T.; Lee, S. Aloesin and arbutin inhibit tyrosinase activity in a synergistic manner via a different action mechanism. Arch. Pharm. Res. 1999, 22, 232-236.
72. Kim, D.; Kim, J.; Baek, D.; Seo, J.; Kho, Y.; Oh, T.; Lee, C. Enhancement of tyrosinase inhibition of the extract of veratrum patulum using cellulase. Biotechnol. Bioeng. 2004, 87, 849-854. (Pubitemid 39265081)
73. Frémont, L. Biological effects of resveratrol. Life Sci. 2000, 66, 663-673.
74. Kim, Y.; Yun, J.; Lee, C.; Lee, H.; Min, K.; Kim, Y. Oxyresveratrol and hydroxystilbene compounds inhibitory effect on tyrosinase and mechanisms of action. J. Biol. Chem. 2002, 227, 16340-16344.
75. Newton, R.; Cook, A.; Roberts, D.; Leonard, J.; Sturm, R. Post-transcriptional regulation of melanin biosynthetic enzymes by cAMP and resveratrol in human melanocytes. J. Invest. Dermatol. 2007, 127, 2216-2227. (Pubitemid 47258483)
76. Yamakoshi, J.; Otsuka, F.; Sano, A.; Tokutake, S.; Saito, M. Lightening effect on ultravioletinduced pigmentation of guinea pig skin by oral administration of a proanthocyanidin-rich extract from grape seeds. Pigment Cell Res. 2003, 16, 629-638. (Pubitemid 37466294)
77. Hachiya, A.; Kobayashi, A.; Yoshida, Y.; Kitahara, T.; Takema, Y.; Imokawa, G. Biphasic expression of two paracrine melanogenic cytokines, stem cell factor and endothelin-1, in ultraviolet b-induced human melanogenesis. Am. J. Pathol. 2004, 165, 2099-2109. (Pubitemid 39578387)
78. Berson, D. Natural antioxidants. J. Drugs Dermatol. 2008, 7, s7-s12.
79. Karg, E.; Odh, G.; Wittbjer, A.; Rosengren, E.; Rorsman, H. Hydrogen peroxide as inducer of elevated tyrosinase level in melanoma cells. J. Invest. Dermatol. 1993, 100, 209s-213s. (Pubitemid 23051700)
80. Farris, P. Topical vitamin C: A useful agent for treating photoaging and other dermatologic conditions. Dermatol. Surg. 2005, 31, 814-818.
81. Kameyama, K.; Sakai, C.; Kondoh, S.; Yonemoto, K.; Nishiyama, S.; Tagawa, M.; Murata, T.; Ohnuma, T.; Quigley, J.; Dorsky, A.; Bucks, D.; Blanock, K. Inhibitory effect of magnesium Lascorbyl- 2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J. Am. Acad. Dermatol. 1996, 34, 29-33. (Pubitemid 26049894)
82. Hakozaki, T.; Takiwaki, H.; Miyamoto, K.; Sato, Y.; Arase, S. Ultrasound enhanced skinlightening effect of vitamin C and niacinamide. Skin Res. Technol. 2006, 12, 105-113.
83. Shimizu, K.; Kondo, R.; Sakai, K.; Takeda, N.; Nagahata, T.; Oniki, T. Novel vitamin E derivative with 4-substituted resorcinol moiety has both antioxidant and tyrosinase inhibitory properties. Lipids 2001, 36, 1321-1326. (Pubitemid 34101225)
84. Fukuzawa, K.; Gebicki, J. Oxidation of α-tocopherol in micelles and liposomes by hydroxy, perhydroxy and superoxide free radicals. Arch. Biochem. Biophys. 1983, 226, 242-251.
85. Choi, C.; Berson, D. Cosmeceuticals. Semin. Cutan. Med. Surg. 2006, 25, 163-168.
86. Funasaka, Y.; Chakraborty, A.; Komoto, M.; Ohashi, A.; Ichihashi, M. The depigmenting effect of α-tocopheryl ferulate on human melanoma cells. Br. J. Dermatol. 1999, 141, 20-29. (Pubitemid 29333689)
87. Minwalla, L.; Zhao, Y.; Cornelius, J.; Babcock, G.; Wickett, R.; Le Poole, I.; Boissy, R. Inhibition of melanosome transfer from melanocytes to keratinocytes by lectins and neoglycoproteins in an in vitro model system. Pigment Cell Res. 2001, 14, 185-194. (Pubitemid 32931057)
88. Ito, Y.; Kanamaru, A.; Tada, A. Centaureidin promotes dendrite retraction of melanocytes by activating Rho. Biochim. Biophys. Acta 2006, 1760, 487-494.
89. Ito, Y.; Kanamaru, A.; Tada, A. Effects of methylophiopogonanone B on melanosome transfer and dendrite retraction. J. Dermatol. Sci. 2006, 42, 68-70. (Pubitemid 43384132)
90. Ito, Y.; Kanamaru, A.; Tada, A. A novel agent, methylophiopogonanone B, promotes Rho activation and tubulin depolymerization. Mol. Cell Biochem. 2007, 297, 121-129. (Pubitemid 46443536)
91. Lin, J.; Chiang, H.; Lin, Y.; Wen, K. Natural products with skin-whitening effects. J.Food Drug Anal. 2008, 16, 1-10.
92. Hakozaki, T.; Minwalla, L.; Zhuang, J.; Chhoa, M.; Matsubara, A.; Miyamoto, K.; Greatens, A.; Hillebrand, G.; Bissett, D.; Boissy, R. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br. J. Dermatol. 2002, 147, 20-31. (Pubitemid 34779433)
93. Greatens, A.; Hakozaki, T.; Koshoffer, A.; Epstein, H.; Schwemberger, S.; Babcock, G.; Bissett, D.; Takiwaki, H.; Arase, S.; Wickett, R.; Boissy, R. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp. Dermatol. 2005, 14, 498-508. (Pubitemid 40883407)
94. Bissett, D.; Miyamoto, K.; Sun, P.; Li, J.; Berge, C. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int. J. Cosmet. Sci. 2004, 26, 231-238. (Pubitemid 39389251)
95. Bissett, D.; Oblong, J.; Berge, C. Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol. Surg. 2005, 31, 860-865.
96. Bissett, D. Topical niacinamide and barrier enhancement. Cutis 2002, 70S, 8-12.
97. Bissett, D.; Oblong, J.; Saud, A.; Berge, C.; Trejo, A.; Biedermann, K. Topical niacinamide provides skin aging appearance benefits while enhancing barrier function. J. Clin. Dermatol. 2003, 32S, 9-18. (Pubitemid 41174152)
98. Van Den Bossche, K.; Naeyaert, J.; Lambert, J. The quest for the mechanism of melanin transfer. Traffic 2006, 7, 769-778.
99. Seiberg, M.; Paine, C.; Sharlow, E.; Andrade-Gordon, P.; Costanzo, M.; Eisinger, M.; Shapiro, S. The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions. Exp. Cell Res. 2000, 254, 25-32. (Pubitemid 30066728)
100. Lin, C.; Chen, N.; Scarpa, R.; Guan, F.; Babiarz-Magee, L.; Liebel, F.; Li, W.; Kizoulis, M.; Shapiro, S.; Seiberg, M. LIGR, a protease-activated receptor-2-derived peptide, enhances skin pigmentation without inducing inflammatory processes. Pigment Cell Melanoma Res. 2008, 21, 172-183.
101. Derian, C.; Eckardt, A.; Andrade-Gordon, P. Differential regulation of human keratinocyte growth and differentiation by a novel family of protease-activated receptors. Cell Growth Diff. 1997, 8, 743-749. (Pubitemid 27287805)
102. Marthinuss, J.; Andrade-Gordon, P.; Seiberg, M. A secreted serine protease can induce apoptosis in Pam212 keratinocytes. Cell Growth Diff. 1995, 6, 807-816.
103. Seiberg, M.; Paine, C.; Sharlow, E.; Andrade-Gordon, P.; Constanzo, M.; Eisinger, M.; Shapiro, S. Inhibition of melanosome transfer results in skin lightening. J. Invest. Dermatol. 2000, 115, 162-167. (Pubitemid 30637183)
104. Babiarz-Magee, L.; Chen, N.; Seiberg, M.; Lin, C. The expression and activation of proteaseactivated receptor-2 correlate with skin color. Pigment Cell Res. 2004, 17, 241-251. (Pubitemid 38724554)
105. Sharlow, E.; Paine, C.; Babiarz, L.; Eisinger, M.; Shapiro, S.; Seiberg, M. The protease-activated receptor-2 upregulates keratinocyte phagocytosis. J. Cell Sci. 2000, 113, 3093-3101.
106. Paine, C.; Sharlow, E.; Liebel, F.; Eisinger, M.; Shapiro, S.; Seiberg, M. An alternative approach to depigmentation by soybean extracts via the inhibition of the PAR-2 pathway. J. Invest. Dermatol. 2001, 116, 587-595. (Pubitemid 32299849)
107. Scott, G.; Deng, A.; Rodriguez-Burford, C.; Seiberg, M.; Han, R.; Babiarz, L.; Grizzle, W.; Bell, W.; Pentland, A. Protease-activated receptor 2, a receptor involved in melanosome transfer, is upregulated in human skin by ultraviolet irradiation. J. Invest. Dermatol. 2001, 117, 1412-1420. (Pubitemid 34032767)
108. Birk, Y. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans. Int. J. Pept. Protein Res. 1985, 25, 113-131.
109. Brenner, M.; Hearing, V. Modifying skin pigmentation-approaches through intrinsic biochemistry and exogenous agents. Drug Discov. Today Dis. Mech. 2008, 5, 189-199.
110. Zhu, W.; Zhang, R. Skin lightening agents. In Cosmetic Formulation of Skin Care Products. Cosmetic Science and Technology Series; Draelos, Z.D., Thaman, L.A., Eds.; Taylor and Francis Group LLC.: New York, NY, USA, 2006; Volume 30, pp. 205-218.
111. Bowe, W.; Shalita, A. Effective over-the-counter acne treatments. Semin. Cutan. Med. Surg. 2008, 27, 170-176.
112. Yamamoto, Y.; Uede, K.; Yonei, N.; Kishioka, A.; Ohtani, T.; Furukawa, F. Effects of alphahydroxy acids on the human skin of Japanese subjects: The rationale for chemical peeling. J. Dermatol. 2006, 1, 16-22.
113. Ando, H.; Funasaka, Y.; Oka, M.; Ohashi, A.; Furumura, M.; Matsunaga, J.; Matsunaga, N.; Hearing, V.; Ichihashi, M. Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids on melanogenesis. J. Lipid Res. 1999, 40, 1312-1316. (Pubitemid 29328534)
114. Halaban, R.; Cheng, E.; Zhang, Y.; Moellmann, G.; Hanlon, D.; Michalak, M.; Setaluri, V.; Hebert, D. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc. Natl. Acad. Sci. USA 1997, 94, 6210-6215. (Pubitemid 27270663)
115. Ando, H.; Ryu, A.; Hashimoto, A.; Oka, M.; Ichihashi, M. Linoleic acid and α-linolenic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch. Dermatol. Res. 1998, 290, 375-381. (Pubitemid 28408561)
116. Nair, X.; Parah, P.; Suhr, L.; Tramposch, K. Combination of 4-hydroxyanisole and all trans retinoic acid produces synergistic skin depigmentation in swine. J. Invest. Dermatol. 1993, 101, 145-149. (Pubitemid 23218689)
117. Berardesca, E.; Ardigò, M.; Berardesca, M.; Cameli, N. Melasma: Current and future treatments. Expert Rev. Dermatol. 2008, 3, 187-193.
118. Lei, T.; Virador, V.; Vieira, W.; Hearing, V. A melanocyte-keratinocyte coculture model to assess regulators of pigmentation in vitro. Anal. Biochem. 2002, 305, 260-268. (Pubitemid 34666799)